IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms.
In: Journal of Clinical Investigation, Jg. 132 (2022-08-01), Heft 15
Online
academicJournal
Zugriff:
Titel: |
IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms.
|
---|---|
Autor/in / Beteiligte Person: | Kuo, Be-Sheng ; Li, Chao-Hung ; Chen, Jiun-Bo ; Shiung, Yu-Yu ; Chu, Chia-Yu ; Lee, Chih-Hung ; Liu, Yaw-Jen ; Kuo, Je-Hung ; Hsu, Cindy ; Su, Hsiao-Wen ; Li, Ywan-Feng ; Lai, Annie ; Ho, Yueh-Feng ; Cheng, Yi-Ning ; Huang, Hong-Xuan ; Lung, Meng-Chung ; Wu, Ming-Syue ; Yang, Fu-Hong ; Lin, Chen-Han ; Tseng, William ; Yang, Jasper ; Lin, Chia-Yin ; Tsai, Pei-Hua ; Chang, Heng-Kwei ; Wang, Yi-Jen ; Chen, Techeng ; Lynn, Shugene ; Liao, Mei-June ; Wang, Chang Yi |
Link: | |
Zeitschrift: | Journal of Clinical Investigation, Jg. 132 (2022-08-01), Heft 15 |
Veröffentlichung: | 2022 |
Medientyp: | academicJournal |
ISSN: | 0021-9738 (print) |
DOI: | 10.1172/JCI157765 |
Sonstiges: |
|